This is a review about current strategies for screening, diagnosis, and treatment of adenovirus and polyomavirus BK infections after kidney transplantation. With regard to the polyomavirus nephropathy, the Banff working group proposed a new staging system to predict the graft outcome.
ABSTRACT:
Modern immunosuppressive therapy has dramatically reduced the incidence of acute rejection and improved graft survival in kidney transplant patients. However, infectious complications remain an important issue. Amongst the various pathogens, viruses such as adenovirus and polyomavirus BK can directly cause acute or chronic graft dysfunction. Adenovirus mainly causes haemorrhagic cystitis and tubulointerstitial nephritis in kidney transplant patients. While patients show apparent clinical symptoms such as fever, dysuria, gross haematuria, frequency and urgency of urination, and most patients show acute graft dysfunction, these symptoms and graft dysfunction are reversible. Polyomavirus BK infection, however, is asymptomatic but graft outcome is poor if the patient develops tissueinvasive nephropathy confirmed by graft biopsy. Recently, an attempt to create a pathological classification for predicting the clinical course has been made by the Banff Working Group on Polyomavirus Nephropathy. With regards to treatment, the basic strategy is a reduction of calcineurin inhibitor and/or antimetabolites, and the effectiveness of several adjunct treatments has been investigated in several clinical trials. There are other unresolved issues, such as the diagnosis of subsequent acute rejection, the definition of remission, methods of resuming immunosuppression and long-term follow-up. Most of all, development of effective vaccines and novel drug discovery are necessary to prevent the development and progression of BKV-associated nephropathy.
In recent years, cumulative progress such as advances in surgical techniques, immunosuppressive therapy, allograft pathology, detection of donor-specific antibodies, and desensitization have contributed to better prognosis for patients undergoing kidney transplantation. Even though modern immunosuppressive therapy has dramatically reduced the incidence of acute rejection and improved graft survival, it is also associated with various post-transplant complications. Common complications are cardiovascular diseases, infectious diseases and malignancies. Infectious diseases constitute the most common post-transplant complications and the second most common cause of death with functioning graft according to the United States Renal Data System Annual Report. 1 Although every infectious pathogen might cause disease in the immunocompromised kidney transplant patient, the most important include the Enterobacteriaceae, which cause urinary tract infections; Pneumocystis jirovecii, causing pneumonia; Candida species, causing invasive fungal infections; herpes viruses; hepatitis viruses and parasites. 2 In addition, it has also been well recognized over the last three decades that specific viruses such as adenovirus (ADV) and polyomavirus BK (BKV) may be directly involved in kidney allograft, and cause acute or chronic graft dysfunction. In this review, current screening, diagnosis, treatment and controversy of kidney allograft viral infections are discussed.
ADV INFECTION IN KIDNEY TRANSPLANT PATIENTS
Adenovirus causes various diseases such as epidemic keratoconjunctivitis, pharyngoconjunctival fever, pneumonia, gastroenteritis and haemorrhagic cystitis. While most ADV infections are self-limiting, those occurring in immunocompromised patients including solid organ or haematopoietic stem cell transplant patients can be severe, or even fatal if the patient develops systemic dissemination. 3, 4 In kidney transplant patients, ADV mainly causes haemorrhagic cystitis and occasionally tubulointerstitial nephritis. In the immunocompromised patient, ADV, specifically subgroups B1 and B2 with the serotypes 7, 11, 34 and 35 have been shown to cause both haemorrhagic cystitis and tubulointerstitial nephritis. 5 
Haemorrhagic cystitis
The most common urologic manifestation of ADV infection in kidney transplant patients is haemorrhagic cystitis, and is diagnosed mainly in the first year after transplantation. Typical clinical symptoms are fever, dysuria, urgency, frequency and gross haematuria. 6 Although several methods are available for specific diagnosis of ADV infection, including viral culture, direct antigen detection, nucleic acid testing and histopathology, the most common diagnostic tool used in clinical practice is the amplification and detection of the viral genome by qualitative polymerase chain reaction (PCR), which shows high sensitivity and provides rapid results. PCR testing allows assessment of both ADV replication and therapeutic response, 7 although there is no clear threshold for diagnosis. Since there is no definitive therapeutic protocol for ADV infection in solid organ transplant patients, the management of ADV infection is largely based on the management and treatment in haematopoietic stem cell transplantation patients, in which the key management strategies are reduction of immunosuppression and supportive care. 8 A case series of ADV-related haemorrhagic cystitis under modern immunosuppression is reported by Watcharananan et al. 9 Amongst 17 patients, 11 (64.7%) developed viraemia accompanied by viruria, and four of 11 patients with higher plasma viral load received intravenous immunoglobulin (IVIG) and cidofovir. All patients achieved viral clearance from urine and plasma, although one patient died from sepsis on the 63rd hospital day (mortality rate 5.9%).
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Tubulointerstitial nephritis It has also been described that the majority of patients presenting with haemorrhagic cystitis have an associated acute graft dysfunction, and in the large majority of patients, renal function returns to baseline after resolution of ADV infection. 9, 10 In the series reported by Watcharananan et al., 9 11 of 17 patients (64.7%) showed an initial rise in serum creatinine, and kidney allograft pathology was described in three cases; tubulointerstitial nephritis (ADV nephritis), acute tubular necrosis, and acute rejection, 9 suggesting that the incidence of concurrent ADV nephritis is not necessarily high among patients with haemorrhagic cystitis. Kidney allograft biopsy is a useful tool in the setting of renal transplantation to provide samples that can show histological changes consistent with viral infection, rejection or other concomitant pathology.
There have been many individual case reports of ADV nephritis. [11] [12] [13] [14] Pathological findings of ADV nephritis are characterized by widespread interstitial mononuclear inflammation, which is difficult to distinguish from acute Tcell-mediated rejection ( Fig. 1) . In some cases, granulomatous changes can be identified. Renal tubules show tubulitis accompanied by tubular destruction, necrosis and viral cytopathic effects, including nuclear enlargement, peripheral condensed chromatin and basophilic nuclear inclusions representing viral particles. 11 There are some reports that
show ADV-infected cells by in situ hybridization or immunohistochemical staining, [11] [12] [13] [14] but unfortunately, there is no commercial antibody with high reliability for ADV staining. Under electron microscopy, 70-80 nm viral particles are visible within the tubular epithelial cells. 11, 12, 14 Treatment of ADV nephritis is similar to that of haemorrhagic cystitis; reduction of immunosuppression and supportive therapy. Hensley et al. reported a case of ADV nephritis in a kidney transplant patient and also described an excellent literature review of 21 previous reports. 13 This review included 11 cases of ADV nephritis after kidney or kidney-pancreas transplantation, while the remaining reports comprised haematopoietic stem cell transplantation or human immunodeficiency virus infection and other clinical settings. The 11 patients were successfully treated with reduction of immunosuppression and/or various adjunctive therapy with IVIG, cidofovir, ribavirin, ganciclovir etc. No patient died, which differed from patients in other clinical settings. 13 Thus, ADV infection after kidney transplantation is potentially life-threatening if the patient develops disseminated infection and multi-organ failure, but ADV nephritis is reversible. 14 
BKV-ASSOCIATED NEPHROPATHY AFTER KIDNEY TRANSPLANTATION
Compared with ADV, BKV infection in kidney transplant patients rarely shows systemic symptoms, but the incidence Recently, the incidence of biopsy-proven BKVAN is supposedly 2-6%. [18] [19] [20] Although the screening and diagnostic procedure is established, the negative impact on graft function remains great because of the absence of effective antiviral drugs and irreversible graft fibrosis even after the clearance of BKV.
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Current strategy for screening and diagnosis of BKVAN
As the initial presentation of BKVAN is insidious, it is recommended that all kidney transplant patients are screened regularly to detect viral replication before development of nephropathy. Both KDIGO and AST guidelines suggest screening for BKV using PCR testing for BKV DNA in plasma. [15] [16] [17] AST also suggests another option, using urinary cytology for decoy cells, electron microscopy in search of viral aggregation, quantitative PCR of urine for >7 log 10 copies/mL of BKV DNA (Fig. 2) , 17 followed by PCR in plasma.
Since the medical cost associated with screening by quantitative PCR is high, most Japanese centres and many centres in other countries perform urinary cytology tests initially, and then investigate the plasma by PCR if persistent urinary decoy cells are found. There are several advantages of testing urine; a high negative predictive value, a longer period before onset of viraemia and nephropathy, and lower costs, especially for cytology. However, physicians should also consider the disadvantages; lower specificity and delayed or lack of viral clearance from the urine after treatment, which might lead to over-reduction of immunosuppression and the risk of subsequent acute rejection. Although screening strategies and several non-invasive tests have been developed, the definitive diagnosis of BKVAN still requires an allograft biopsy. Under light microscopy, varying degrees of interstitial inflammation rich in lymphocytes and plasma cells can be observed (Fig. 3A) . This interstitial inflammatory response is not pathognomonic and is difficult to distinguish from acute T-cell mediated rejection. More specific findings include intranuclear inclusions in tubular epithelial cells (Fig. 3B) . The cytopathic changes are often associated with tubular cell necrosis resulting in virus shedding into the tubular lumen and denudation of the tubular basement membrane (Fig. 3B) . Typical cytopathic changes in tubular cells are focally observed and may cause misdiagnosis through sampling error, especially in the early stages of the disease. BKVinduced cytopathic changes are more easily observed in the tubulus of the medulla (Fig. 3C) . Since it is possible to miss BKVAN with a single biopsy core, taking two cores of kidney tissue with at least one containing medullary parenchyma is recommended. 16 In addition to observation under light microscopy, most centres also probe biopsy specimens with antibodies against Simian Virus 40 large T-antigen (Fig. 3D) or perform in situ hybridization.
Pathological staging system
The ability to predict the clinical outcome is important in patients who develop BKVAN. As BKVAN is a pathological diagnosis, there has been much interest in exploring the effects of histologic variables on graft outcome. A composite system to stage the disease based on viral cytopathic effect, extent of inflammation, and severity of fibrosis was first proposed by Drachenberg et al., 23 Figure 3B , but does not take into account the degree of inflammation when assigning staging. 21, 25 The
Banff Working Group performed a multicentre retrospective study, which revealed that stage C was associated with greater changes in serum creatinine from baseline to the peak point and poor graft outcome, but the clinical significance of stages A and B were unclear. 26 That same multicentre study has not reached a conclusion, and the Banff Working Proposal 2009 was not incorporated into the Banff classification. The AST system also has problems; most biopsies are classified into pattern B, and pattern A is rare, possibly diagnosed by protocol biopsy. In pattern B, subclassification into B1, B2 and B3 according to the area affected does not provide sufficient data to inform statistical discriminating power for clinical studies. The Banff Working Group performed in-depth statistical analysis using a retrospective cohort of 192 patients to identify the factors associated with clinical presentation and found that two independent histologic variables were significant; intra-renal viral load (Banff pvl score) and the extent of interstitial fibrosis (ci score). They proposed a new classification using those parameters in 2013 (Banff Working Proposal 2013), 27 and recently published the final results of a multicentre study. 28 The new scoring system of the Banff Working Proposal 2013 is shown in Figure 4 . In the multicentre study, they evaluated three clinical parameters: (i) graft function at the time of diagnosis, (ii) graft function after the index biopsy, and (iii) graft failure, and demonstrated that the serum creatinine (sCr) levels at diagnosis, changes in sCr at diagnosis from baseline, and sCr changes from baseline after 12 and 24 months were significantly higher in the class three group than those in the class 1 and class 2 groups. Importantly, values were also significantly different between class 1 and class 2. Although the rates of resolution, defined as first repeat biopsy without nephropathy and/or first repeat plasma PCR without detectable BK viraemia, amongst the three studied groups were not statistically different, graft failure rates within 24 months were 16% in class 1, 31% in class 2, and 50%
BKV viruria
Positive "definitive PyVAN" in class 3 patients, suggesting that the Banff Working Proposal 2013 has a strong discriminating power for graft outcome in BKVAN.
Suggested treatment of BKV infection
Although there are few controlled studies available to guide the treatment of BK viraemia and BKVAN, the generally recommended approach is reduction of overall immunosuppression when the patient develops sustained viraemia and nephropathy (Fig. 2) . Currently, two strategies are recommended by the AST guidelines, these being: (i) dose reduction of calcineurin inhibitor by 25-50% in one or two steps, followed by reducing antimetabolites by 50%, followed by discontinuing the latter; (ii) reduction of antimetabolites by 50%, followed by reducing calcineurin inhibitors by 25-50%, followed by discontinuing antimetabolites. 16 The AST guidelines also suggest adjunct treatments, including switching tacrolimus to cyclosporine, switching calcineurin inhibitor to low-dose sirolimus, switching mycophenolic acid A B C D to leflunomide, and administration of cidofovir, IVIG and fluoroquinolones. 16, 17 However, none of these treatment strategies have enough clinical evidence to become standard practice. 29 More recently, everolimus, a well-studied inhibitor of mammalian target of rapamycin, has been suggested to reduce the risk of viral infections and post-transplant cancer. The latest meta-analysis suggested that an everolimusbased regimen could reduce the risk of cytomegalovirus infection, while the study neither confirmed nor ruled out a risk reduction of BKV infection. 30 Indeed, there are only a few randomised controlled studies focused on BKV infection in kidney transplant patients, with small study populations and different study designs. 31, 32 Further investigation is necessary to confirm the effect of everolimus on BKV infection.
Unresolved issues in BKV infection
There are several unresolved issues in the management of BKVAN. First, the definition of remission is unclear. Some studies defined the resolution of disease as when negative viral staining is identified in follow-up biopsy specimens and/or negative BK viraemia by repeated PCR testing. 21, 28 In the first few months after diagnosis and reduction of immunosuppression, it is well known that sCr levels show a temporal increase, and tubulointerstitial inflammation worsens in early re-biopsy tissues. 33, 34 Recently, graft inflammation in BKVAN has been suggested to be a benign reconstitution type of inflammation to clear BKV from the allograft kidney. 28, 33, 34 However, it is uncertain how long this process may persist, how to distinguish this process from subsequent acute T-cell-mediated rejection, and when to resume immunosuppression as it is difficult to distinguish these inflammatory processes by morphological observation. The other issues recently reported are late complications including de novo donor-specific antibody (DSA) production and renourinary tumorigenesis. Cheungpasitporn et al. investigated 904 kidney transplant patients including 30 with BK viraemia and 43 BKVAN, and demonstrated that BKVAN but not BK viraemia was the independent risk factor for de novo DSA production. 35 Detailed mechanisms are unknown, but it was speculated that graft inflammation in BKVAN and acute T-cell-mediated rejection in addition to the reduction of immunosuppression are important for DSA production, even though antiviral inflammation could be a benign, healing process as described above. As compared with premature graft loss by BKVAN, the potential oncogenicity of BKV has attracted less attention, but remains important as it is potentially life-threatening. Kenan et al.
described an excellent literature review of urological malignancy in transplant recipients, revealing that cancer developed mainly in the bladder and allograft kidney, and histology was predominantly that of urothelial cancer and transitional cell cancer. 36 They also described their own case of urothelial cancer in the allograft kidney, performed highthroughput sequencing of tumour DNA, and demonstrated the integration of viral genes and non-coding control region rearrangement in tumour cells, which could cause genetic instability and persistent upregulation of early gene products, stimulating host cell proliferation. 36 These findings suggest that we need to take into account potential tumorigenesis in kidney transplant patients with BKV reactivation, and consider cancer screening thereafter.
CONCLUSIONS
Adenovirus and BKV infections are associated with kidney allograft dysfunction, but the clinical features of these two infections are quite different. ADV infection is rare, but it can be diagnosed immediately because the patients develop clear symptoms. Although ADV can be lethal in kidney transplant patients with disseminated infection, if adequate supportive care and reduction of immunosuppression is received, both allograft and patient outcomes are good. On the other hand, BKV infection is significantly associated with chronic graft dysfunction and therefore has been more intensively investigated. Although screening for viral replication and pathological diagnosis have been established, the incidence of graft loss is still high because reduction of immunosuppression to clear BKV is often challenging. Development of effective genotype-specific vaccines and novel drug discovery are necessary to prevent the development and progression of BKVAN.
